WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004028545) A COMBINATION OF A LONG-ACTING &bgr;2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/028545    International Application No.:    PCT/SE2003/001486
Publication Date: 08.04.2004 International Filing Date: 24.09.2003
Chapter 2 Demand Filed:    25.03.2004    
IPC:
A61K 31/167 (2006.01), A61K 31/58 (2006.01), A61K 45/06 (2006.01)
Applicants: ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE) (For All Designated States Except US).
TROFAST, Jan [SE/SE]; (SE) (For US Only).
WESTERGREN-THORSSON, Gunilla [SE/SE]; (SE) (For US Only)
Inventors: TROFAST, Jan; (SE).
WESTERGREN-THORSSON, Gunilla; (SE)
Agent: ASTRAZENECA AB; Global Intellectual Property, S-151 85 Södertälje (SE)
Priority Data:
0202837-1 25.09.2002 SE
0300106-2 16.01.2003 SE
Title (EN) A COMBINATION OF A LONG-ACTING &bgr;2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
(FR) COMBINAISON D'UN AGONISTE $G(B)2 A ACTION PROLONGEE ET D'UN GLUCOCORTICOSTEROIDE DANS LE TRAITEMENT DE MALADIES FIBROTIQUES
Abstract: front page image
(EN)The invention relates to new uses of glucocorticosteroids and long-acting &bgr;2-agonists in the treatment of various fibrotic diseases, e.g. idiopathic pulmonary fibrosis, allergic alveolitis and cystic fibrosis. The preferred combination of active substances consists of budesonide and formoterol fumarate dihydrate.
(FR)L'invention concerne de nouvelles applications de glucocorticostéroïdes et d'agonistes $g(b)2 à action prolongée dans le traitement de diverses maladies fibrotiques, p. ex. la fibrose pulmonaire idiopathique, l'alvéolite allergique et la mucoviscidose. La combinaison préférée de principes actifs associe budesonide et dihydrate de fumarate de formoterol.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)